Pfizer plans to seek FDA approval in the Fall for COVID-19 vaccine of young children
According to reports, the biopharmaceutical giant Pfizer is planning to seek emergency use authorization to mass distribute its COVID-19 vaccines for children between the ages of 2 and 11.
Pfizer plans on applying for authorization with the U.S. Food and Drug Administration for full approval of the vaccine by September 2021.
“We are essentially nearing the end of vaccinating those that were willingly waiting to get in line to get it. And so, the next push is going to be I think more critical than ever,” said one epidemiology expert in a news report.
Pfizer’s COVID-19 vaccine has been critical in profoundly reducing the number of confirmed cases through the United States.
“Full approval from the FDA could help boost confidence in the vaccine, especially among people who may have lingering worries about how quickly it was developed,” said the expert in the news release.